Precision BioSciences Inc (DTIL)
Drugs • Health Care
July 31, 2026 Precision BioSciences Set to Release Q2 2026 Financial Results Precision BioSciences is set to release its Q2 2026 financial results on August 6. The report will shed light on the company's innovative ARCUS® gene editing platform and its ongoing research in therapeutic advancements.
July 27, 2026 Precision BioSciences Announces Strategic Leadership Changes to Propel Clinical Advancements Precision BioSciences has announced strategic leadership changes to accelerate clinical development in gene editing therapies. Alex Kelly will become COO, while Naresh Tanna takes on the CFO role, with a focus on enhancing operational and financial strategies. These changes aim to bolster clinical initiatives, particularly for diseases with high unmet needs.
July 10, 2026 Precision BioSciences Announces Inducement Awards to New Employees Precision BioSciences has announced inducement awards for new employees to strengthen its team in gene editing. The commitment reflects its dedication to addressing unmet medical needs through its ARCUS® platform.
June 29, 2026 Precision BioSciences Joins the Russell 2000® Index: A Strategic Move for Enhanced Visibility Precision BioSciences has been included in the Russell 2000 Index, enhancing its visibility among institutional investors. This strategic move coincides with the company's focus on advancing gene editing therapies through its ARCUS platform, which targets significant medical needs.
May 27, 2026 Precision BioSciences Announces Groundbreaking PBGENE-HBV Data at EASL 2026 Precision BioSciences has unveiled groundbreaking data from its PBGENE-HBV study at EASL 2026, demonstrating the elimination of cccDNA in chronic hepatitis B patients. This treatment may signal a shift from lifelong care to potential cures, with promising safety and efficacy results.
May 21, 2026 Precision BioSciences Sets Stage for Investor Webcast on PBGENE-HBV Data Precision BioSciences will host an investor webcast on May 27, 2026, to discuss new data from the PBGENE-HBV program at the EASL Congress. The presentation will focus on important findings from the Phase 1 ELIMINATE-B trial, a unique approach to treating chronic hepatitis B by targeting cccDNA.
May 05, 2026 Precision BioSciences Reports First Quarter 2026 Financial Results and Business Update Precision BioSciences reported strong financial results for Q1 2026, showcasing progress in its clinical programs for hepatitis B and Duchenne muscular dystrophy. With a robust pipeline and strategic focus, the company aims to meet critical health needs while maintaining financial health.
May 05, 2026 Precision BioSciences Inc. Reports Strong Progress in 2026 Q1, Focused on Gene Editing Innovations Precision BioSciences reported significant progress in Q1 2026, focusing on gene editing therapies like PBGENE-HBV and PBGENE-DMD. The company showed substantial revenue growth and maintained a strong balance sheet, positioning itself for future advancements in genetic disease treatment.
April 30, 2026 Precision BioSciences Set to Reveal First Quarter 2026 Financial Results Precision BioSciences will release its Q1 2026 financial results on May 5, offering insights into its ARCUS platform and gene editing advancements. Investors await key updates on the company's financial health and pipeline.
April 29, 2026 Precision BioSciences Activates First Clinical Trial Site for PBGENE-DMD Precision BioSciences has begun its Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, targeting Duchenne muscular dystrophy in young patients. This innovative gene therapy aims to improve treatment efficacy for the most affected demographic, with Arkansas Children’s Hospital as the first clinical site.
April 28, 2026 Precision BioSciences Set to Present Promising Data on PBGENE-DMD at ASGCT 2026 Annual Meeting Precision BioSciences is set to present new preclinical data on its PBGENE-DMD program, aimed at treating Duchenne muscular dystrophy, at the ASGCT 2026 Annual Meeting. The therapy shows potential for significant functional improvement in early-juvenile mice, highlighting its role in addressing unmet medical needs.
April 22, 2026 Precision BioSciences Announces Late-Breaking Presentation at EASL Congress 2026 Precision BioSciences will present groundbreaking data on PBGENE-HBV during the EASL Congress 2026, showcasing significant advancements in treating chronic hepatitis B. The presentation will highlight the elimination of cccDNA in liver biopsies, marking a potential breakthrough in HBV therapy.
April 15, 2026 Precision BioSciences Expands ELIMINATE-B Trial into Europe Precision BioSciences is expanding its ELIMINATE-B clinical trial into France and Romania, aimed at developing PBGENE-HBV, a novel gene editing therapy for chronic hepatitis B. This strategic move is expected to boost patient enrollment and advance the fight against this severe health issue.
April 08, 2026 Precision BioSciences Announces Participation in 25th Annual Needham Virtual Healthcare Conference Precision BioSciences will participate in the 25th Annual Needham Virtual Healthcare Conference, presenting its groundbreaking gene editing technologies. The corporate presentation is on April 14, 2026, where stakeholders can learn about their innovative therapies aimed at genetic diseases.
March 12, 2026 Precision BioSciences Reports Encouraging Financial Results and Business Updates for 2025 Precision BioSciences reports significant financial gains and clinical progress for 2025, including advancements in its PBGENE-HBV and PBGENE-DMD programs. The company achieved a net income turnaround and is well-positioned for future growth in gene editing therapies.
March 12, 2026 Precision BioSciences Inc. Reports 2025 Annual Results: Navigating Challenges and Advancements in Gene Editing Precision BioSciences Inc. released its 2025 annual report, showcasing advancements in clinical trials for PBGENE-HBV and PBGENE-DMD despite financial challenges. The company navigates a complex landscape as it focuses on strategic partnerships and ongoing research to address critical health needs.
March 11, 2026 Precision BioSciences Announces Key Patent Allowances for PBGENE-HBV Program Precision BioSciences has received two patent allowances for its PBGENE-HBV program, crucial for developing gene editing solutions for chronic Hepatitis B. These patents strengthen the company's intellectual property and support ongoing clinical trials aimed at providing a potential cure.
March 10, 2026 Precision BioSciences Unveils Promising Preclinical Data for PBGENE-DMD at MDA Conference Precision BioSciences unveiled promising preclinical data for PBGENE-DMD at the MDA Conference, showing significant muscle function improvements and durability. This innovative therapy aims to provide long-term benefits for Duchenne muscular dystrophy patients and is poised for clinical trials in 2026.
March 09, 2026 Precision BioSciences Set to Release Q4 and Fiscal Year 2025 Results Precision BioSciences will announce its fourth quarter and fiscal year 2025 results on March 12, 2026. The company continues to advance its ARCUS® gene editing platform, focusing on innovative therapies targeting genetic diseases. Stakeholders await insights into the company's financial health and strategic initiatives.
March 09, 2026 Precision BioSciences Secures FDA Fast Track Designation for PBGENE-DMD Precision BioSciences has received FDA Fast Track designation for its innovative gene therapy, PBGENE-DMD, aimed at treating Duchenne muscular dystrophy. This regulatory milestone accelerates development towards clinical trials, offering hope to patients with unmet medical needs.
March 02, 2026 Precision BioSciences Secures $7.5 Million Clinical Milestone Payment from TG Therapeutics Precision BioSciences has announced a $7.5 million milestone payment from TG Therapeutics due to advancements in the Phase 1 trial of azer-cel for multiple sclerosis. This payment underscores the strategic partnership's success and the potential of gene editing technology in treating serious medical conditions.
February 18, 2026 Precision BioSciences Showcases Promising Advances in DMD Treatment Precision BioSciences is set to present groundbreaking findings on PBGENE-DMD, a novel gene editing therapy for Duchenne Muscular Dystrophy, at the 2026 MDA Conference. Early studies show significant improvements in muscle function, offering hope for effective treatment options for DMD patients.
February 11, 2026 Precision BioSciences Gains FDA Clearance for Groundbreaking DMD Treatment Precision BioSciences has gained FDA clearance for its groundbreaking gene therapy, PBGENE-DMD, aimed at treating Duchenne muscular dystrophy (DMD). This first-in-class treatment uses a unique gene excision approach to restore dystrophin protein production, targeting a critical patient demographic. The FUNCTION-DMD trial is set to begin, promising new hope for effective DMD therapies.
January 12, 2026 Precision BioSciences Sets Strategic Priorities for 2026: Focus on Gene Editing Breakthroughs Precision BioSciences has set strategic priorities for 2026, emphasizing its gene editing advancements in PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The company is optimistic about clinical trial progress and financial stability, positioning itself as a leader in the gene editing sector.
December 23, 2025 Precision BioSciences Grants Inducement Awards as Part of Growth Strategy Precision BioSciences has granted 8,224 RSUs to a new employee as part of its strategy to attract top talent and enhance its ARCUS gene editing platform. This move aligns with their commitment to innovation in gene therapy and addresses the competitive nature of the biopharmaceutical industry.
November 19, 2025 Precision BioSciences Unveils Promising Data from ELIMINATE-B Trial at Hep-DART 2025 Precision BioSciences will present key findings from its ELIMINATE-B trial at Hep-DART 2025, showcasing PBGENE-HBV, a groundbreaking gene editing therapy for chronic hepatitis B. This innovative treatment aims to eliminate the virus's persistence, offering hope to millions affected globally.
November 10, 2025 Precision BioSciences Showcases Groundbreaking PBGENE-HBV Data at AASLD 2025 Precision BioSciences showcased pivotal PBGENE-HBV data at AASLD 2025, highlighting its safety and effectiveness in reducing HBsAg levels in chronic Hepatitis B patients. The trial's results suggest a promising path towards a functional cure and underscore the potential of gene editing technology in treating infectious diseases.
November 10, 2025 Precision BioSciences Announces $75 Million Offering Precision BioSciences has launched a $75 million underwritten offering to sell shares and warrants, aimed at supporting its gene editing research and development. The proceeds will enhance its ARCUS® platform, addressing unmet medical needs. The offering is backed by a diverse group of investors, demonstrating confidence in the company's innovative approach.
November 03, 2025 Precision BioSciences Reports Third Quarter 2025 Financial Results and Strategic Updates Precision BioSciences reported its Q3 2025 financial results, showcasing advancements in its gene editing therapies, particularly PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy. The company is actively pursuing clinical trials and maintaining a stable financial position amidst strategic developments.
November 03, 2025 Precision BioSciences Inc. Reports Mixed Results in Q3 2025 Precision BioSciences Inc. released its Q3 2025 results, revealing significant financial losses alongside advancements in gene editing therapies for chronic Hepatitis B and DMD. The company faces liquidity challenges but remains focused on clinical trial progress and regulatory approvals.
October 31, 2025 Precision BioSciences Set to Reveal Q3 2025 Financial Results Precision BioSciences is set to announce its Q3 2025 financial results on November 3. The company, known for its ARCUS® gene editing platform, is focused on innovative therapies for unmet medical needs, including programs targeting Hepatitis B and Duchenne Muscular Dystrophy.
October 14, 2025 Precision BioSciences Set to Present PBGENE-HBV Data at AASLD 2025 Precision BioSciences is set to present groundbreaking data on its PBGENE-HBV gene editing therapy at AASLD 2025. This innovative approach aims to cure chronic hepatitis B, a condition affecting 300 million people worldwide, offering hope for a functional cure.
October 09, 2025 Precision BioSciences Advances Gene Editing with Publication in Nucleic Acids Research Precision BioSciences has published groundbreaking findings on its ARCUS gene editing platform in *Nucleic Acids Research*. The study reveals high-efficiency transgene insertion and versatile editing capabilities, promising advancements in therapies for genetic diseases.
October 07, 2025 Precision BioSciences Activates First U.S. Clinical Trial Site for Groundbreaking ELIMINATE-B Trial Precision BioSciences has launched its first U.S. clinical trial site for the ELIMINATE-B Phase 1 trial, focusing on a novel gene editing therapy for chronic hepatitis B. With over 300 million affected globally, this trial aims to evaluate a potential cure that addresses the root causes of the disease.
September 30, 2025 Precision BioSciences Set to Present Groundbreaking Data on PBGENE-DMD at World Muscle Society Congress Precision BioSciences is set to present groundbreaking preclinical data on PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy, at the World Muscle Society Congress. The findings indicate significant improvements in muscle function and dystrophin expression, potentially revolutionizing treatment options for patients.
August 07, 2025 Precision BioSciences Inc. Reports Q2 2025 Results: Navigating Challenges and Progressing in Gene Editing Precision BioSciences Inc. reported significant financial losses in Q2 2025, driven by the conclusion of a major agreement. Despite challenges, the company is advancing its PBGENE-HBV and PBGENE-DMD programs, aiming for breakthroughs in gene editing therapies while focusing on operational efficiency.
May 15, 2025 Precision BioSciences Inc. Reports Q1 2025 Financial Results: Navigating Challenges with Promising Developments Precision BioSciences Inc. reported a net loss of $20.56 million for Q1 2025, a stark decline from the previous year's profit. Despite financial challenges, the company is advancing its clinical programs, including promising trials for PBGENE-HBV and PBGENE-DMD.
May 15, 2025 Precision BioSciences Reports First Quarter 2025 Financial Results and Business Update Precision BioSciences reported its Q1 2025 financial results, highlighting key advancements in gene editing, particularly the PBGENE-HBV and PBGENE-DMD programs. The company's focus remains on delivering impactful clinical data amid a challenging financial landscape.
May 14, 2025 Precision BioSciences Accelerates Development of PBGENE-DMD: A Game-Changer for Duchenne Muscular Dystrophy Precision BioSciences announced the acceleration of PBGENE-DMD, a gene editing therapy for Duchenne Muscular Dystrophy, showcasing promising preclinical data. This innovative approach aims to restore dystrophin protein production and improve muscle function, with potential for lifelong benefits.
May 08, 2025 Precision BioSciences Set to Report First Quarter 2025 Results on May 15 Precision BioSciences is set to announce its Q1 2025 financial results on May 15, highlighting advancements in its ARCUS® gene editing platform. The report will offer insights into the company's pipeline and market potential as it addresses significant unmet medical needs.
May 07, 2025 Precision BioSciences Unveils Promising Safety Data for PBGENE-HBV at EASL Congress Precision BioSciences has shared promising initial safety data from its PBGENE-HBV trial for chronic hepatitis B at EASL 2025. The treatment shows encouraging safety signals and is well-tolerated by patients, highlighting a significant step forward in addressing this global health challenge.
May 01, 2025 Precision BioSciences Showcases Innovations in Gene Editing at ASGCT Annual Meeting Precision BioSciences will present five abstracts at the ASGCT Annual Meeting, focusing on its ARCUS gene editing platform. The company aims to revolutionize treatments for chronic hepatitis B and other genetic diseases, showcasing promising data from various clinical and preclinical programs.
April 29, 2025 Precision BioSciences Announces Inducement Awards for New Employees Precision BioSciences has approved inducement awards for two new employees, granting 11,339 RSUs to bolster its workforce. This strategy aims to attract top talent to advance its ARCUS® gene editing technologies, enhancing therapeutic outcomes for genetic diseases.
April 15, 2025 Precision BioSciences Secures FDA Fast Track Designation for PBGENE-HBV Precision BioSciences has received FDA Fast Track designation for its gene editing therapy PBGENE-HBV, aimed at curing chronic hepatitis B by eliminating cccDNA. The therapy is currently in the Phase 1 ELIMINATE-B trial, which may revolutionize treatment options for the 300 million affected globally.
April 01, 2025 Precision BioSciences to Showcase Innovations at 24th Annual Needham Virtual Healthcare Conference Precision BioSciences will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, showcasing its ARCUS® gene editing platform. This event highlights the company's advancements in gene therapies targeting genetic and infectious diseases, positioning it as a leader in the biotech field.
March 26, 2025 Precision BioSciences Inc. Reports 2024 Annual Results: A Year of Transition and Growth Precision BioSciences Inc. has reported significant growth in 2024, marked by successful partnerships and advancements in clinical trials. The company achieved a notable revenue increase and a return to profitability, setting the stage for future developments in the gene editing sector.
March 26, 2025 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Results Precision BioSciences reported significant financial results for Q4 2024, showcasing its progress in gene editing therapies, particularly for chronic Hepatitis B. The company is set to advance its clinical trials and maintain a strong financial position heading into 2025.
February 24, 2025 Precision BioSciences to Showcase Promising DMD Research at MDA Conference Precision BioSciences will present pivotal research on Duchenne muscular dystrophy (DMD) at the MDA Conference 2025, showcasing its ARCUS gene editing platform. The presentation aims to highlight a novel therapeutic approach capable of restoring crucial muscle function.
February 19, 2025 Precision BioSciences Announces Initial Results from PBGENE-HBV Clinical Trial Precision BioSciences has announced initial results from its ELIMINATE-B clinical trial for PBGENE-HBV, showing a favorable safety profile and significant reduction in HBsAg levels in participants. The trial aims to treat chronic Hepatitis B and expand to diverse patient populations in the U.S. and U.K.
January 30, 2025 SWOT Analysis of Precision BioSciences Inc in 2025 This SWOT analysis of Precision BioSciences Inc in 2025 highlights its innovative ARCUS gene editing technology and strong IP portfolio. However, the company faces challenges such as operating losses and intense competition, which it must navigate for future growth.
November 04, 2024 Precision BioSciences Inc. Reports Q3 2024 Financial Results: Challenges and Growth Prospects Ahead Precision BioSciences Inc. announced a significant revenue decline in Q3 2024, reporting $0.6 million compared to $13.1 million in Q3 2023. Despite increased losses, the company is focusing on strategic partnerships and innovative research to drive future growth, particularly in gene editing and clinical trials.
August 01, 2024 Precision BioSciences Inc. Reports Strong Q2 2024 Results Precision BioSciences Inc. reported impressive Q2 2024 results, with revenues soaring to $49.9 million, driven by new licensing agreements. Strategic collaborations and a focus on innovative gene editing therapies position the company for future growth.
May 13, 2024 Precision BioSciences Inc. Reports Strong Q1 2024 Results: A Shift Towards Growth Precision BioSciences Inc. reported a strong Q1 2024 with revenues of $17.6 million, a significant turnaround from last year's losses. The company is leveraging strategic collaborations and a robust cash position to advance its gene editing therapies.
March 27, 2024 Precision BioSciences Inc. Reports 2023 Annual Results: A Year of Strategic Moves Amidst Financial Challenges Precision BioSciences' 2023 annual report reveals significant revenue growth alongside ongoing financial challenges. Key strategic transactions and collaborations aim to enhance its innovative gene editing pipeline, despite substantial operating losses.